A Phase 2 interventional study of Vericiguat in Heart Failure and Cognitive Impairment, sponsored by University of Alberta. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by University of Alberta · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing vericiguat in Heart Failure — 7 open to participants now, 8 under way, 1 of them phase 3. vericiguat · Heart Failure.
Among the 19 studies testing vericiguat in Heart Failure, this one is the 11th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 14th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 19 studies testing vericiguat in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Khawaja Danish Ali · Sites in Pakistan
Ages 25–65
Guangdong Provincial People's Hospital · Sites in China
Ages 18–80
Merck Sharp & Dohme LLC · Sites in United States, Belgium, Brazil and 27 more countries
Ages 29 days–17 yrs
National Institute of Cardiovascular Diseases, Pakistan
Ages 18–80
Dongying Zhang · Sites in China
Ages 18+
By country, each count listing its studies:
vericiguat: first FDA approval 2021 (VERQUVO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 6
First in 2013; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 120 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 130 across the 19 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
30 studies in Heart Failure by University of Alberta: 11 open now, 11 under way, none of them phase 3. Of 17 finished, 0 (0%) have results posted.
Among the 30 studies in Heart Failure by University of Alberta, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 24th registered.
University of Alberta’s Heart Failure studies by the year they started, since 2002.
1 of the studies testing vericiguat in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07697833National Institute of Cardiovascular Diseases, PakistanComparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients | 2027-05-15 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing vericiguat in Heart Failure, from their registry updates:
Among University of Alberta’s 30 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
CONVERGE-HF is a randomized, open label, phase IIb trial evaluating the effect of sGC stimulator, Vericiguat versus standard of care on imaging markers and blood markers of cerebral and coronary small vessel diseases, function status, cognitive status, quality of life and clinical events in patients with heart failure and mild-to-moderate cognitive impairment. Patients will be randomized and allocated to either vericiguat or standard of care, for 26 weeks including the greater than 4 weeks timeframe for the uptitrations to the target dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. Uptitrated gradually every 2 weeks to 5 mg daily and then to the target dose of 10 mg daily.
Drug: Vericiguat
Conventional management of heart failure and mild-to-moderate cognitive impairment.
Tablet - 2.5 mg, 5 mg, 10 mg
Also known as: Verquvo
Change in the lateral ventricular volumes.
To determine whether in patients with heart failure and mild-to-moderate cognitive impairment, the 26 weeks of treatment with sGC stimulator, vericiguat versus standard of care lead to greater reduction (or smaller increase) in lateral ventricular volume in brain MRI as a proxy for the preservation of brain microvasculature and preventing brain tissue loss.
Time frame: 26 weeks
Blood Biomarkers (a)
To determine the difference in the change in cardiac ischemia and strain markers measured by cardiac troponin, IGFBP-7, and NT-proBNP between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.
Time frame: 26 weeks
Blood Biomarkers (b)
To determine the difference in the change of brain-related marker of cis p-tau between patients with chronic CV disease and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.
Time frame: 26 weeks
Imaging Biomarkers (Cardiac)
To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat, versus standard of care in terms of the change in CMR perfusion test results for perfusion deficits indicative of coronary microvascular impairment.
Time frame: 26 weeks
Imaging Biomarkers (Brain)
To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care in terms of the change in brain MRI peak skeletonized mean diffusivity of the white matter and change in white matter hypersensitivity volume indicative of cerebral small vessel disease.
Time frame: 26 weeks
Clinical and patient-reported outcomes (MoCA)
To compare the change of MoCA scores in 26 weeks between groups who were treated with vericiguat versus standard of care.
Time frame: 26 weeks
Clinical and patient-reported outcomes (KCCQ-12)
To compare the change of health-related quality of life (assessed via KCCQ-12) in 26 weeks between groups who were treated with vericiguat versus standard of care. The KCCQ-12 has a standardized format and has been validated for paper, electronic or telephone delivery.
Time frame: 26 weeks
Clinical and patient-reported outcomes (6MWT)
To compare the change of functional status assessed via 6-minute walk test (6MWT) in 26 weeks between groups who were treated with vericiguat versus standard of care. The 6MWT will be performed as outlined by the American Thoracic Society by an assessor blinded to treatment allocation.61 6MWT will be assessed both in-person and using the validated virtual approach utilizing Walk.Talk.Track app.
Time frame: 26 weeks
Clinical and patient-reported outcomes (RBANS)
To compare the change of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores between groups. The RBANS is a widely-used battery for identifying and characterizing abnormal cognitive decline in elderly adults. Its level of difficulty is appropriate for the range from normal cognition to moderately severe dementia.
Time frame: 26 weeks
Clinical events - Death
(all cause)
Time frame: 26 weeks
Clinical events - Hospitalizations
(all cause)
Time frame: 26 weeks
Clinical events - Emergency Department Visits
(all cause)
Time frame: 26 weeks
Clinical events - Stroke
Time frame: 26 weeks
Clinical events - Other
Time frame: 26 weeks
Plan to share: No — There are no plans to share IPD at this time.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 37 months after the start.
Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 37 months is close to that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vericiguat